The latest market report published by Credence Research, Inc. “Global Genital Herpes Treatment Drugs Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global genital herpes treatment drugs market is expected to expand at a CAGR of 4.9% from 2018 to 2026.
Genital herpes is the most common form of sexually transmitted disease in sexually active individuals. No noticeable signs have been documented in the early stage of infection, but as the disease progresses, genital lesions, cold sores, irregular discharge, and severe pain during urination are clinically manifested. It spreads through genital, vaginal, and anal contact. It is important to note that herpes infection is not healed only the symptoms are suppressed to facilitate relief in ill patients. Safe sex practice, early diagnosis and sexual hygiene are the main preventive measures to prevent the spread of genital herpes infection. There is a growing trend in the treatment of genital herpes infection, with biologists focusing primarily on developing vaccines to improve immunity in ill patients and address the problem of lesion recurrence.
Acyclovir is still the largest drug class in the market for genital herpes care drugs. The key characteristics responsible for the supremacy of acyclovir are its excellent therapeutic effectiveness, dose tolerance with minimal toxicity. It is currently the first available drug for the treatment of genital herpes with a prescribed dose of 200 mg five times daily for 10 days. Famciclovir has gained prominence due to its higher oral bioavailability used in the treatment of genital herpes patients suffering from recurrence of the lesion.
North America is still the largest regional segment of the market for genital herpes care drugs. According to the Center for Disease Control and Prevention (CDC), genital herpes occurs 1 in every 6 people in the United States. Rising prevalence of sexually transmitted diseases and effective treatment recommendations drive the development of the market for genital herpes drugs in North America.
Affordable reimbursement scenario and domicile of major players such as AstraZeneca, Plc., GlaxoSmithkline, Plc. & Novartis AG. Propel the genital herpes treatment drugs market growth in the European region. Asia Pacific will register rapid growth during the forecast period from 2018 to 2026 owing to the rising prevalence of HSV-1 infected patients, increasing public health awareness and presence of huge generic drugs for the treatment of genital herpes infection.
Pharmaceutical companies providing medication for the treatment of genital herpes infection are AstraZeneca, Plc., Apotheca, Inc., Asahi Kasei Pharma Corporation, Carlsbad Technology, Inc., GlaxoSmithkline, Plc., Mylan N.V., Novartis AG., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Zydus Pharmaceuticals, Inc.
Key Market Movements:
Rising prevalence of sexually transmitted disease worldwide
Increasing public health awareness and affordable reimbursement scenario drive the genital herpes treatment drugs market
Excellent product pipeline catering therapeutics vaccines to bolster patient immunity such as GEN-003 and VCL-HB01